相似文献
1
Doctor takes "march of shame" to atone for drug company payments.
BMJ. 2008 Jan 5;336(7634):20-1. doi: 10.1136/bmj.39437.473576.0F.
2
Drug company payments: Speakers should declare funding.
BMJ. 2008 Feb 2;336(7638):234. doi: 10.1136/bmj.39465.455995.3A.
3
Australian regulator insists on greater transparency of industry payments to doctors.
BMJ. 2014 Oct 20;349:g6335. doi: 10.1136/bmj.g6335.
4
Drug company payments: Put declaration in abstracts.
BMJ. 2008 Feb 16;336(7640):345. doi: 10.1136/bmj.39486.497639.3A.
5
Pharma PR or medical education?
Hastings Cent Rep. 2005 Mar-Apr;35(2):6.
6
Drug companies will have to report all payments to US doctors from March 2014.
BMJ. 2013 Feb 7;346:f826. doi: 10.1136/bmj.f826.
7
Money for drugs: should physicians be paid for pharmaceutical development and clinical investigations?
Mo Med. 2011 Sep-Oct;108(5):320-9.
8
Conflicts of interest: part 1: Reconnecting the dots--reinterpreting industry-physician relations.
N Engl J Med. 2015 May 7;372(19):1860-4. doi: 10.1056/NEJMms1502493.
9
Conflicts of Interest.
N Engl J Med. 2015 Aug 20;373(8):779. doi: 10.1056/NEJMc1507811.
10
Conflicts of Interest.
N Engl J Med. 2015 Aug 20;373(8):778-9. doi: 10.1056/NEJMc1507811.
引用本文的文献
1
Drug company payments: Speakers should declare funding.
BMJ. 2008 Feb 2;336(7638):234. doi: 10.1136/bmj.39465.455995.3A.
Zotero 插件